Singapore, Sept. 23 -- US-based Angelini Pharma, part of the privately owned Angelini Industries, and Sovargen, a South-Korean biotechnology company, have signed an exclusive global option agreement for the development and commercialisation of Sovargen's innovative brain health asset SVG105.

Under the terms of the agreement, Angelini Pharma and Sovargen will collaboratively lead the pre-clinical development efforts for SVG105 and, following an initial option period, Angelini Pharma will have the right to advance the compound into clinical development and commercialisation outside of the Republic of Korea, China, Hong Kong, Macau and Taiwan.

SVG105 is a potentially first-in-class anti-sense oligonucleotide technology to target mTOR (mamm...